Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 2, pp 296–299 | Cite as

Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France

  • Marine AuffretEmail author
  • Benjamin Rolland
  • Anne-Sylvie Caous
  • Sylvie Deheul
  • Johana Béné
  • Olivier Cottencin
  • Régis Bordet
  • Sophie Gautier
Short Research Report

Abstract

Background Community pharmacists’ liability is involved when they dispense off-label prescriptions (OLPs). However, their attitudes to off-label prescribing are little known, while in France off-label baclofen use for alcohol dependence is increasing. Objective To determine community pharmacists’ attitudes to off-label prescribing of baclofen. Method A postal questionnaire was sent to 219 community pharmacies in the Nord-Pas-de-Calais region, France, previously identified as delivering at least five boxes of oral baclofen monthly. The questionnaire examined whether pharmacists delivered baclofen for alcohol dependence, how pharmacists detected off-label prescribing of baclofen, who were the most frequent prescribers (general practitioners or specialists), and pharmacists’ attitudes to OLPs. Results Eighty pharmacies responded (36.5 %). Detection criteria for OLPs were supra-threshold dose (77.3 %) and “off-label” written on prescription (52.5 %). General practitioners were the most frequent prescribers of off-label baclofen. Pharmacists were more likely to refuse to fill prescriptions not marked “off-label” (6.0 %) than correctly marked prescriptions (1.5 %). 85 % of respondents considered they lacked information on off-label use. Conclusion Although community pharmacists felt they were poorly informed on off-label baclofen, the majority nevertheless delivered the drug. Since our survey, off-label baclofen prescribing has been strictly controlled in France. Pharmacists’ current attitudes will need further evaluation.

Keywords

Alcohol dependence Baclofen Community pharmacists Drug dispensing France Off-label 

Notes

Acknowledgments

The research team would like to thank pharmacists who agreed to complete the questionnaire.

Funding

No special funding was received.

Conflicts of interest

B.R. and O.C. are associate investigators in the ALPADIR clinical trial, a placebo-controlled study of the efficacy of baclofen in maintaining abstinence in alcohol dependence funded by the pharmaceutical company Ethypharm S.A. B.R. participated as an unpaid speaker at a conference organised by the Institut de Recherche Scientifique sur les Boissons Alcoolisées (IREB), an organisation funded by companies in the alcohol industry. O.C. participated in symposia organised by Lundbeck, Pfizer, Servier, Reckit Benckiser, Bouchara Recordati and Janssen Cilag. S.G., T.D., R.B., M.A. and S.D. have no conflict of interest.

Supplementary material

11096_2015_74_MOESM1_ESM.doc (28 kb)
Supplementary material 1 (DOC 27 kb)

References

  1. 1.
    Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Loi no. 2011—2012 du 29 décembre 2011 relative au renforcement de la sécurité sanitaire du médicament et des produits de santé. Journal Officiel de la République Française. 2011.Google Scholar
  3. 3.
    Auffret M, Rolland B, Deheul S, Lecomte L, Cottencin O, Bordet R, et al. Le dispositif CAMTEA. Involvement of pharmacists in systems for supervising off-label medications: example of the CAMTEA system for the prescription of baclofen in alcohol use disorder in Northern France. Ann Pharm Fr. 2014;72:28–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Geoffroy PA, Auffret M, Deheul S, Bordet R, Cottencin O, Rolland B. Baclofen-induced manic symptoms: case report and systematic review. Psychosomatics. 2014;55:326–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Auffret M, Rolland B, Deheul S, Loche V, Hennaux C, Cottencin O, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48:656–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012;47:577–80.CrossRefPubMedGoogle Scholar
  7. 7.
    Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Point d’information—Utilisation du baclofène dans l’alcoolodépendance: actualisation juin. 2012. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Utilisation-du-baclofene-dans-le-traitement-de-l-alcoolo-dependance-Point-d-information-actualisation-juin-2012/%28language%29/fre-FR. Accessed 26 Sept 2014.
  8. 8.
    Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Commission évaluation initiale du rapport entre les bénéfices et les risques des produits de santé. Compte-rendu de la réunion du 4 juillet 2013. http://ansm.sante.fr/var/ansm_site/storage/original/application/693a562657d53e271bf6836f9ce03f57.pdf. Accessed 29 Sept 2014.
  9. 9.
    Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Une recommandation temporaire d’utilisation (RTU) est accordée pour le baclofène—Point d’information. 14 mars 2014. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Une-recommandation-temporaire-d-utilisation-RTU-est-accordee-pour-le-baclofene-Point-d-information Accessed September 296 2014.
  10. 10.
    Dupouy J, Fournier JP, Jouanjus É, Palmaro A, Poutrain JC, Oustric S, et al. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns–a cohort study. Eur Neuropsychopharmacol. 2014;24:192–9.CrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Marine Auffret
    • 1
    Email author
  • Benjamin Rolland
    • 2
    • 3
  • Anne-Sylvie Caous
    • 4
  • Sylvie Deheul
    • 4
  • Johana Béné
    • 5
  • Olivier Cottencin
    • 2
    • 6
  • Régis Bordet
    • 3
    • 4
  • Sophie Gautier
    • 3
    • 5
  1. 1.Centre Régional de PharmacovigilanceCHRU de LilleLille CedexFrance
  2. 2.Service d’AddictologieCHRU LilleLille CedexFrance
  3. 3.EA 1046, Laboratoire de PharmacologieUniversité de Lille 2Lille CedexFrance
  4. 4.Centre d’Evaluation et d’Information sur la Pharmacodépendance du Nord-Pas de CalaisCHRU LilleLille CedexFrance
  5. 5.Centre Régional de Pharmacovigilance du Nord-Pas de CalaisCHRU LilleLille CedexFrance
  6. 6.LNFP, EA 4559Université Lille Nord de FranceLille CedexFrance

Personalised recommendations